ReviewCancer reports (Hoboken, N.J.)2021
Recommendations for streamlining precision medicine in breast cancer care in Latin America.
Review in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review.The oncologist · 2026Review
- Disparities in breast cancer screening, stage at diagnosis, and treatment in Brazil: a warning of the need to change public policies.BMC public health · 2026Article
- Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.International journal of environmental research and public health · 2025Review
- Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.JCO global oncology · 2024Article
- Partnering to Strengthen Health Systems and Improve Access to Quality Cancer Care.JCO global oncology · 2022Article
- Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitative study.Lancet regional health. Americas · 2022Article
- Integration of artificial intelligence and precision oncology in Latin America.Frontiers in medical technology · 2022Review
- Recommendations for streamlining precision medicine in breast cancer care in Latin America.Cancer reports (Hoboken, N.J.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
Abstract
backgroundThe incidence of breast cancer (BC) in LMICs has increased by more than 20% within the last decade. In areas such as Latin America (LA), addressing BC at national levels evoke discussions surrounding fragmented care, limited resources, and regulatory barriers. Precision Medicine (PM), specifically companion diagnostics (CDx), links disease diagnosis and treatment for better patient outcomes. Thus, its application may aid in overcoming these barriers. RECENT
findingsA panel of LA experts in fields related to BC and PM were provided with a series of relevant questions to address prior to a multi-day conference. Within this conference, each narrative was edited by the entire group, through numerous rounds of discussion until a consensus was achieved. The panel proposes specific, realistic recommendations for implementing CDx in BC in LA and other LMIC regions. In these recommendations, the authors strived to address all barriers to the widespread use and access mentioned previously within this manuscript.
conclusionThis manuscript provides a review of the current state of CDx for BC in LA. Of most importance, the panel proposes practical and actionable recommendations for the implementation of CDx throughout the Region in order to identify the right patient at the right time for the right treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.